Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631

Septerna, Inc.

Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.
SEP-479 PTH1R agonist on track for Phase 1 initiation in first half of 2026.
Cash $548.7M at Dec 31, 2025; runway at least into 2029 (includes $195M upfront from Novo Nordisk).
Q4 2025 revenue $24.1M (collaboration revenue); net loss $10.7M vs $20.7M loss in Q4 2024.
Appointed Mark A. Wilson as chief legal officer in January 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Septerna, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $24.1 million for the fourth quarter of 2025 and $46.0 million for the full year ended December 31, 2025, net income Net loss was $10.7 million for the fourth quarter of 2025 and $48.9 million for the full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $24.1 million for the fourth quarter of 2025 and $46.0 million for the full year ended December 31, 2025
Net income: Net loss was $10.7 million for the fourth quarter of 2025 and $48.9 million for the full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 9, 2026, Septerna, Inc. (the “Company”) announced its financial results and business highlights for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Septerna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-098489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.